Guided Therapeutics Hires New CEO

Norcross, Ga.-based Guided Therapeutics Inc. has hired executive Gene Cartwright as its next CEO, taking the place of Mark L. Faupel who has transitioned to the role of chief scientific officer.

“Gene has great experience in the diagnostics market both in the development and introduction of new diagnostics technologies as well as extensive successful commercial experience with global businesses,” said Michael James, chairman of the board of directors for Guided Therapeutics. “The company is poised for accelerated growth and we are confident that Gene is the right person to move the company forward.”

Gene brings over 30 years of experience working in the in vitro diagnostics industry. He joins Guided Therapeutics from Omnyx LLC, a joint venture between GE Healthcare and the University of Pittsburgh Medical Center, where, as CEO for over four years, he founded and managed the successful development of products for the field of digital pathology.

Prior to his work with Omnyx, he was president of Molecular Diagnostics for GE Healthcare. Prior to GE, he was divisional vice president/general manager for Abbott Diagnostics’ Molecular Diagnostics business. In his 24-year career at Abbott, he also served as divisional vice president for U.S. marketing for five years.

“I’m very excited to join Guided Therapeutics at this critical stage in the company’s history,” Cartwright said. “They have introduced their CE marked Luviva product internationally and I look forward to growing the sales for this important new global product in the cervical cancer diagnostics market. I also will work diligently to achieve [U.S. Food and Drug Administration] approval for Luviva in the United States and build on the great work that has been done to date by Mark Faupel and the Guided Therapeutics team.”

Cartwright earned an A.B. from Dartmouth College, a Master’s of Management degree from Northwestern University’s Kellogg School of Management, and a Ph.D. in chemistry from Stanford University.

Guided Therapeutics makes a testing platform based on its patented biophotonic technology that uses light for the early detection of disease at the cellular level. Luviva, the company’s first product, is an advanced cervical scan, a non-invasive device used to detect cervical disease instantly and at the point of care.